Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL vs ESTARYLLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) provides contraception by inhibiting gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Prevention of pregnancy,Acne vulgaris (off-label),Dysmenorrhea (off-label),Endometriosis (off-label)
FDA-approved: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.,Off-label: Acne vulgaris (for norgestimate-containing pills), management of menstrual disorders (e.g., dysmenorrhea, abnormal uterine bleeding), hormone therapy for transgender women (non-standardized).,Note: Off-label uses are not FDA-approved for this specific formulation.
One tablet (norethindrone 1 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 placebo tablets. For first cycle, start on first Sunday after menstruation begins or on day 1 of menstrual cycle.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
Terminal half-life: norethindrone 7-8 hours, ethinyl estradiol 13-27 hours; clinical context: steady-state achieved in 3-5 half-lives
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Norethindrone is metabolized primarily via reduction and conjugation; ethinyl estradiol is metabolized via CYP3A4 and undergoes glucuronidation. Both undergo enterohepatic circulation.
Ethinyl estradiol is primarily metabolized by CYP3A4, with conjugation to glucuronides and sulfates. Norgestimate is rapidly metabolized to its active metabolite, norelgestromin, and further to levonorgestrel; involvement of CYP2C19 and CYP3A4 in norgestimate metabolism is noted.
Renal: ~60% as metabolites, biliary/fecal: ~40% as glucuronide conjugates
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Norethindrone: 80% bound to albumin and SHBG; ethinyl estradiol: 97% bound to albumin
Ethinyl estradiol: 97-98% bound to albumin, with minor binding to sex hormone-binding globulin
Norethindrone: 4 L/kg, indicates extensive tissue distribution; ethinyl estradiol: 4-5 L/kg
Ethinyl estradiol: approximately 2.8 L/kg; indicates extensive tissue distribution
Oral: norethindrone ~65%, ethinyl estradiol ~40-45% due to first-pass metabolism
Oral: approximately 55% due to first-pass metabolism; consistent in healthy females
No specific GFR-based dose adjustments recommended; use with caution in renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment or end-stage renal disease due to lack of data.
Contraindicated in Child-Pugh class B or C (severe hepatic impairment) or active liver disease. For mild impairment (Child-Pugh A), use with caution and monitor liver function.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; dose adjustment not specifically defined, but alternative contraception recommended.
Not indicated for use before menarche; dosing for postmenarchal adolescents same as adult.
Approved for use in postmenarchal adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). No weight-based dosing required.
Not indicated for use in postmenopausal women; no geriatric dosing established due to lack of indication.
Not indicated in postmenopausal women. No specific geriatric dosing; contraindicated in women over 60 years due to increased thromboembolic risk.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age and heavy smoking (≥15 cigarettes/day) and is significant in women over 35. Women over 35 who smoke should not use this product.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptives. This risk increases with age (especially in women over 35 years of age) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Cerebrovascular disease,Hepatic neoplasia (benign and malignant),Gallbladder disease,Hypertension,Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis, optic neuritis),Headache (including migraine),Breakthrough bleeding and spotting,Depression,Malignant neoplasms (breast, cervical),Effect on pregnancies (fetal harm if used during pregnancy),Lactation (may decrease milk production),Hereditary angioedema,Chloasma,Laboratory test interference
Thrombotic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., MI, stroke). Discontinue if thrombotic event occurs.,Cardiovascular disease: Avoid in women with uncontrolled hypertension, diabetes with vascular involvement, or history of thromboembolic disease.,Cigarette smoking: Strongly advise cessation, especially in women over 35.,Liver disease: Discontinue if jaundice or cholestasis develops; contraindicated in acute viral hepatitis or severe cirrhosis.,Hormone-dependent malignancies: Increased risk of breast cancer (current use) and cervical cancer; avoid if known or suspected breast cancer.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate and lipid metabolism: Monitor glucose and lipids in predisposed patients; may impair glucose tolerance and increase triglycerides.,Headache: Evaluate if new-onset or worsening migraine, especially with focal neurological symptoms.,Uterine bleeding: Rule out pregnancy if amenorrhea occurs; irregular bleeding may require evaluation.,Depression: Monitor for mood changes; discontinue if severe depression recurs.,Angioedema: Risk in women with hereditary angioedema.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Benign or malignant liver tumors, or active liver disease,Hypersensitivity to any component,Women over 35 who smoke cigarettes
Known or suspected pregnancy,Current or past venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism),Current or past arterial thrombosis (e.g., myocardial infarction, stroke) or prodromal conditions (e.g., angina, transient ischemic attack),Known thrombophilic disorders (e.g., Factor V Leiden, prothrombin mutation, antithrombin deficiency),History of cerebrovascular or coronary artery disease,Uncontrolled hypertension (sustained >160/100 mm Hg),Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura) in women over 35,Current or past breast cancer, or other estrogen- or progestin-sensitive cancer,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis) or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component of Estarylla,Use of highly active antiretroviral therapy (HAART) containing ritonavir or direct-acting antivirals for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir) due to potential for hepatotoxicity
Avoid grapefruit juice as it may alter metabolism; no other significant food interactions reported.
There are no known significant food interactions. Grapefruit juice may increase estrogen levels but clinical significance is unclear; consider moderate intake.
Pregnancy category X. Contraindicated in pregnancy. First trimester: Increased risk of congenital anomalies, including cardiac and limb defects, due to progestin and estrogen exposure. Second and third trimesters: Risk of feminization of male fetus, urogenital sinus abnormalities, and clitoral hypertrophy from progestin (norethindrone). Post-fertilization: Disruption of fetal development.
Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations from inadvertent exposure, but increased risk of cardiovascular and limb defects in some studies. Second and third trimesters: Associated with fetal harm, including cardiovascular effects (e.g., congenital heart defects) and possible estrogenic effects, though data are limited. Postnatal effects: Potential long-term developmental effects unknown. Overall risk is low but not zero; avoid use in pregnancy.
Norethindrone and ethinyl estradiol are excreted in breast milk in small amounts (M/P ratio approximately 0.5-1.0 for norethindrone). May reduce milk production and quality. Use only if clearly needed and with caution, as long-term effects on infant are unknown. Typically not recommended during breastfeeding.
Estarylla is excreted in breast milk in small amounts (ethinyl estradiol: M/P ratio ~0.2; levonorgestrel: M/P ratio ~0.3-0.4). Combined hormonal contraceptives may reduce milk production and affect milk composition, especially in early postpartum. Use is generally not recommended until breastfeeding is well-established (at least 6 weeks postpartum). For later use, progestin-only methods are preferred. Monitor infant for jaundice and growth.
No dose adjustments applicable as drug is contraindicated in pregnancy. No studies indicate need for dose change during pregnancy due to pharmacokinetic changes, as use is not recommended.
Estarylla is contraindicated in pregnancy. No dosing adjustments are recommended because it should not be used. Pregnancy alters pharmacokinetics of oral contraceptives (e.g., increased volume of distribution, altered hepatic metabolism), but no dose changes are indicated due to contraindication. If inadvertently taken, discontinue immediately.
Monitor for thromboembolic events, especially in smokers over 35. Use as part of a combined oral contraceptive regimen; may cause breakthrough bleeding. Check for drug interactions with rifampin, carbamazepine, and certain antibiotics.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It is indicated for prevention of pregnancy. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed dose management: take as soon as remembered, use backup contraception if more than 24 hours late. May reduce menstrual cramps and acne. Not recommended in patients with history of estrogen-dependent neoplasia, liver disease, or uncontrolled hypertension.
Take at the same time daily to maintain consistent hormone levels.,Report signs of blood clots (leg pain, chest pain, sudden headache) immediately.,Use backup contraception if you miss a dose or start a new medication.,Do not smoke while taking this medication, especially if over 35 years old.,This medication does not protect against sexually transmitted diseases.
Take one pill daily at the same time each day.,If you miss a pill, take it as soon as remembered; use backup contraception if more than 24 hours late.,Do not smoke while taking this medication, especially if over 35.,Report any signs of blood clots: leg pain, chest pain, shortness of breath, or sudden vision changes.,This medication does not protect against HIV or other STDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL vs ESTARYLLA, answered by our medical review team.
NORINYL is a Combined Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) provides contraception by inhibiting gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. ESTARYLLA is a Combined Oral Contraceptive that works by Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL and ESTARYLLA depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL is: One tablet (norethindrone 1 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 placebo tablets. For first cycle, start on first Sunday after menstruation begins or on day 1 of menstrual cycle.. The standard adult dose of ESTARYLLA is: One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL and ESTARYLLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. First trimester: Increased risk of congenital anomalies, including cardiac and limb defects, due to progestin and estrogen expos. ESTARYLLA is classified as Category C. Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.